China
· Delayed Price · Currency is CNY Cathay Biotech Statistics
Total Valuation
Cathay Biotech has a market cap or net worth of CNY 29.41 billion. The enterprise value is 29.68 billion.
| Market Cap | 29.41B |
| Enterprise Value | 29.68B |
Important Dates
The next estimated earnings date is Thursday, April 3, 2025.
| Earnings Date | Apr 3, 2025 |
| Ex-Dividend Date | Jul 24, 2024 |
Share Statistics
Cathay Biotech has 581.32 million shares outstanding. The number of shares has decreased by -0.40% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 581.32M |
| Shares Change (YoY) | -0.40% |
| Shares Change (QoQ) | -2.46% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 17.94% |
| Float | 212.76M |
Valuation Ratios
The trailing PE ratio is 60.24.
| PE Ratio | 60.24 |
| Forward PE | n/a |
| PS Ratio | 9.92 |
| PB Ratio | 2.56 |
| P/TBV Ratio | 2.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 60.97 |
| EV / Sales | 10.04 |
| EV / EBITDA | 35.84 |
| EV / EBIT | 54.25 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 1.57 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 3.27% and return on invested capital (ROIC) is 2.08%.
| Return on Equity (ROE) | 3.27% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 2.08% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 1.64M |
| Profits Per Employee | 269,956 |
| Employee Count | 1,803 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +14.64% in the last 52 weeks. The beta is 0.67, so Cathay Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | +14.64% |
| 50-Day Moving Average | 46.25 |
| 200-Day Moving Average | 43.21 |
| Relative Strength Index (RSI) | 59.72 |
| Average Volume (20 Days) | 3,710,230 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cathay Biotech had revenue of CNY 2.96 billion and earned 486.73 million in profits. Earnings per share was 0.84.
| Revenue | 2.96B |
| Gross Profit | 547.04M |
| Operating Income | 547.04M |
| Pretax Income | 545.74M |
| Net Income | 486.73M |
| EBITDA | 827.99M |
| EBIT | 547.04M |
| Earnings Per Share (EPS) | 0.84 |
Balance Sheet
The company has 4.64 billion in cash and 1.30 billion in debt, giving a net cash position of 3.34 billion or 5.74 per share.
| Cash & Cash Equivalents | 4.64B |
| Total Debt | 1.30B |
| Net Cash | 3.34B |
| Net Cash Per Share | 5.74 |
| Equity (Book Value) | 14.99B |
| Book Value Per Share | 19.74 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 18.50%, with operating and profit margins of 18.50% and 16.46%.
| Gross Margin | 18.50% |
| Operating Margin | 18.50% |
| Pretax Margin | 18.46% |
| Profit Margin | 16.46% |
| EBITDA Margin | 28.01% |
| EBIT Margin | 18.50% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.19, which amounts to a dividend yield of 0.38%.
| Dividend Per Share | 0.19 |
| Dividend Yield | 0.38% |
| Dividend Growth (YoY) | 5.56% |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | 0.40% |
| Shareholder Yield | 0.78% |
| Earnings Yield | 1.65% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on July 20, 2022. It was a forward split with a ratio of 1.4.
| Last Split Date | Jul 20, 2022 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |